Initiation of first Marinosolv clinical trial (Ph III)
October 19, 2018
Corporate News
The “Budesolv 10” study team during the initiation visit at the Vienna Challenge Chamber. Left to right: Dr. Reinhard Riedlsperger, Mag. Martina Görner, CRS Riedlsperger GmbH; Dr. Patrick Lemell, Dr. Petra Zieglmayer, Ing. Rene Zieglmayer, Vienna Challenge Chamber; Dr. Nicole Unger-Manhart, Dr. Eva Prieschl-Grassauer, Dr. Andreas Goessl, Mag. Sabine Grohmann, Marinomed Biotech AG

Marinomed Biotech AG is proud to announce the initiation of their Ph III clinical trial “BDS_18_01” with their first Marinosolv-based investigational medicinal product, “Budesolv 10 micrograms, nasal spray”. This nasal spray will be the first budesonide-based treatment for allergic rhinitis (hay fever) that delivers the active substance in dissolved form, thereby allowing treatment with a lower dose of budesonide than marketed products in a preservative-free configuration. The patent-protected development product will be tested for the indication of allergic rhinitis in the setting of the clinical research facility VCC (Vienna Challenge Chamber), the first and world-leading study center that performs clinical allergy trials under controlled and reproducible conditions in Vienna (www.vcc.at).